Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Account Payables
Amounts the company owes suppliers for goods and services received.
Aktis Oncology, Inc.NASDAQ: AKTS
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables of $1.23M in Q1 FY2026
Q1 FY2026 account payables was $1.23M. Over 3 fiscal years it compounded at +52.5% a year.
Context
- Account payables amounted to 0.2% of total assets at the end of Q1 FY2026.
- Account payables increased in 2 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 1.74M USD
- Year-over-year change
- -9.4%
- 3-year CAGR
- +52.5%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.74M | -9.4% |
| FY2024 | 2024-12-31 | 1.92M | +100.4% |
| FY2023 | 2023-12-31 | 957K | +95.3% |
| FY2022 | 2022-12-31 | 490K | — |
Account Payables vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 account payables of $1.23M is the lowest of the 6 companies compared; the peer median is $4.46M.
- Account payables amounts to 0.2% of total assets for AKTS, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $30.16M | +3.6% | +19.0% | 2.8% | |
| Mar 2026 | $5.97M | -46.3% | +14.3% | 0.9% | |
| Sep 2026 | $4.46M | -27.4% | +11.6% | 0.9% | |
| Mar 2026 | $4.29M | -35.2% | -0.8% | 2.0% | |
| Mar 2026 | $2.57M | +28.3% | -19.1% | 1.9% | |
| Mar 2026 | $1.23M | — | +52.5% | 0.2% | |
| Peer median (excluding AKTS) | $4.46M | -27.4% | +11.6% | 1.9% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.